Literature DB >> 29246894

Global Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated With Heart Failure and Preserved or Reduced Ejection Fraction.

Ahmed U Fayyaz1,2, William D Edwards2, Joseph J Maleszewski1,2, Ewa A Konik1, Hilary M DuBrock3, Barry A Borlaug1, Robert P Frantz1, Sarah M Jenkins4, Margaret M Redfield5.   

Abstract

BACKGROUND: We hypothesized that pulmonary venous hypertension in heart failure (HF) leads to predominate remodeling of pulmonary veins and that the severity of venous remodeling is associated with the severity of pulmonary hypertension (PH) in HF.
METHODS: Patients with HF (n=108; 53 preserved and 55 reduced ejection fraction) with PH (HF-PH; pulmonary artery systolic pressure [PASP] ≥40 mm Hg) were compared to normal controls (n=12) and patients with primary pulmonary veno-occlusive disease (PVOD; n=17). In lung specimens from autopsy (control, HF-PH, and 7 PVOD) or surgery (10 PVOD), quantitative histomorphometry was performed in all analyzable arteries (n=4949), veins (n=7630), and small indeterminate vessels (IV; n=2168) to define percent medial thickness (arteries) and percent intimal thickness (%IT) (arteries, veins, and IV) relative to external diameter.
RESULTS: The average arterial percent medial thickness (control, 6.9; HF-PH, 11.0; PVOD, 15.0), arterial %IT (control, 4.9; HF-PH, 14.9; PVOD, 31.1), venous %IT (control, 14.0; HF-PH, 24.9; PVOD, 43.9), and IV %IT (control, 10.6; HF-PH, 25.8; PVOD, 50.0) in HF-PH were higher than controls (P<0.0001 for all) but lower than PVOD (P≤0.005 for all). PASP (mm Hg) was lower in HF-PH (median, 59 [interquartile range, 50-70]) than in PVOD (median, 91 [interquartile range, 82-103]). PASP correlated with arterial percent medial thickness (r=0.41) and arterial %IT (r=0.35) but more strongly with venous %IT (r=0.49) and IV %IT (r=0.55) (P<0.0001 for all). Associations between PASP and venous or IV %IT remained significant after adjusting for arterial percent medial thickness and %IT and did not vary by HF type. In patients with right heart catheterization (30 HF-PH, 14 PVOD), similar associations between the transpulmonary gradient and pulmonary vascular remodeling existed, with numerically stronger associations for venous and IV %IT. Although the PASP was slightly higher in patients with HF-PH with right ventricular dysfunction, pulmonary vascular remodeling was not more severe. Pulmonary vascular remodeling severity was associated with reductions in the diffusing capacity of the lungs.
CONCLUSIONS: In HF, PH is associated with global pulmonary vascular remodeling, but the severity of PH correlates most strongly with venous and small IV intimal thickening, similar to the pattern observed in PVOD. These findings expand our understanding of the pathobiology of PH in HF.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  diffusing capacity of the lungs for carbon monoxide; heart failure; heart failure with preserved ejection fraction; pulmonary function; pulmonary hypertension; right ventricle

Mesh:

Year:  2017        PMID: 29246894      PMCID: PMC5915920          DOI: 10.1161/CIRCULATIONAHA.117.031608

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  41 in total

1.  Venous and arterial changes in pulmonary veno-occlusive disease, mitral stenosis and fibrosing mediastinitis.

Authors:  I Chazova; I Robbins; J Loyd; J Newman; V Tapson; V Zhdaov; B Meyrick
Journal:  Eur Respir J       Date:  2000-01       Impact factor: 16.671

2.  Right ventricular function in heart failure with preserved ejection fraction: a community-based study.

Authors:  Selma F Mohammed; Imad Hussain; Omar F AbouEzzeddine; Omar F Abou Ezzeddine; Hiroyuki Takahama; Susan H Kwon; Paul Forfia; Véronique L Roger; Margaret M Redfield
Journal:  Circulation       Date:  2014-11-12       Impact factor: 29.690

3.  The pulmonary vessels in mitral stenosis.

Authors:  D HEATH; W WHITAKER
Journal:  J Pathol Bacteriol       Date:  1955-10

Review 4.  Pathology of pulmonary hypertension.

Authors:  Rubin M Tuder; Elvira Stacher; Jeffrey Robinson; Rahul Kumar; Brian B Graham
Journal:  Clin Chest Med       Date:  2013-10-17       Impact factor: 2.878

5.  Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study.

Authors:  Milton Packer; John McMurray; Barry M Massie; Abraham Caspi; Vincent Charlon; Alain Cohen-Solal; Wolfgang Kiowski; William Kostuk; Henry Krum; Barry Levine; Paolo Rizzon; Jordi Soler; Karl Swedberg; Susan Anderson; David L Demets
Journal:  J Card Fail       Date:  2005-02       Impact factor: 5.712

6.  Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension: A Pathophysiological Continuum.

Authors:  Christian F Opitz; Marius M Hoeper; J Simon R Gibbs; Harald Kaemmerer; Joanna Pepke-Zaba; J Gerry Coghlan; Laura Scelsi; Michele D'Alto; Karen M Olsson; Silvia Ulrich; Werner Scholtz; Uwe Schulz; Ekkehard Grünig; Carmine D Vizza; Gerd Staehler; Leonhard Bruch; Doerte Huscher; David Pittrow; Stephan Rosenkranz
Journal:  J Am Coll Cardiol       Date:  2016-07-26       Impact factor: 24.094

7.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Authors:  Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272

8.  Pulmonary veins in the normal lung and pulmonary hypertension due to left heart disease.

Authors:  James M Hunt; Brian Bethea; Xiang Liu; Aneta Gandjeva; Pradeep P A Mammen; Elvira Stacher; Marina R Gandjeva; Elisabeth Parish; Mario Perez; Lynelle Smith; Brian B Graham; Wolfgang M Kuebler; Rubin M Tuder
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-09-13       Impact factor: 5.464

9.  Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: pulmonary hypertension and heart failure.

Authors:  Wayne L Miller; Diane E Grill; Barry A Borlaug
Journal:  JACC Heart Fail       Date:  2013-08-05       Impact factor: 12.035

10.  Pathology of the pulmonary vasculature. Correlation with clinical and haemodynamic data.

Authors:  C A Wagenvoort
Journal:  Schweiz Med Wochenschr       Date:  1985-09-28
View more
  64 in total

Review 1.  Pulmonary Hypertension Due to Left Heart Disease: an Update.

Authors:  Mandar A Aras; Mitchell A Psotka; Teresa De Marco
Journal:  Curr Cardiol Rep       Date:  2019-05-27       Impact factor: 2.931

2.  Exercise unmasks distinct pathophysiologic features in heart failure with preserved ejection fraction and pulmonary vascular disease.

Authors:  Thomas M Gorter; Masaru Obokata; Yogesh N V Reddy; Vojtech Melenovsky; Barry A Borlaug
Journal:  Eur Heart J       Date:  2018-08-07       Impact factor: 29.983

Review 3.  Heart Failure With Preserved Ejection Fraction In Perspective.

Authors:  Marc A Pfeffer; Amil M Shah; Barry A Borlaug
Journal:  Circ Res       Date:  2019-05-24       Impact factor: 17.367

4.  The β-Adrenergic Agonist Albuterol Improves Pulmonary Vascular Reserve in Heart Failure With Preserved Ejection Fraction.

Authors:  Yogesh N V Reddy; Masaru Obokata; Katlyn E Koepp; Alexander C Egbe; Brandon Wiley; Barry A Borlaug
Journal:  Circ Res       Date:  2019-01-18       Impact factor: 17.367

Review 5.  Pulmonary Artery Denervation: Update on Clinical Studies.

Authors:  Hang Zhang; Shao-Liang Chen
Journal:  Curr Cardiol Rep       Date:  2019-09-05       Impact factor: 2.931

6.  Pulmonary Venous Remodeling in Pulmonary Hypertension: The Veins Take Center Stage.

Authors:  Jane A Leopold
Journal:  Circulation       Date:  2018-04-24       Impact factor: 29.690

7.  The neurohormonal basis of pulmonary hypertension in heart failure with preserved ejection fraction.

Authors:  Masaru Obokata; Garvan C Kane; Yogesh N V Reddy; Vojtech Melenovsky; Thomas P Olson; Petr Jarolim; Barry A Borlaug
Journal:  Eur Heart J       Date:  2019-12-01       Impact factor: 29.983

8.  Endothelin-1, cardiac morphology, and heart failure: the MESA angiogenesis study.

Authors:  Peter J Leary; Nancy S Jenny; David A Bluemke; Steven M Kawut; Richard A Kronmal; Joao A Lima; Bradley A Maron; David D Ralph; Samuel G Rayner; John J Ryan; Zachary L Steinberg; Karen D Hinckley Stukovsky; Ryan J Tedford
Journal:  J Heart Lung Transplant       Date:  2019-08-10       Impact factor: 10.247

Review 9.  Insights into the pulmonary vascular complications of heart failure with preserved ejection fraction.

Authors:  Yen-Chun Lai; Longfei Wang; Mark T Gladwin
Journal:  J Physiol       Date:  2018-12-30       Impact factor: 5.182

10.  Pulmonary Vascular Pressures and Gas Exchange Response to Exercise in Heart Failure With Preserved Ejection Fraction.

Authors:  Caitlin C Fermoyle; Glenn M Stewart; Barry A Borlaug; Bruce D Johnson
Journal:  J Card Fail       Date:  2020-08-01       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.